Immuneering (IMRX) EBITDA (2020 - 2026)

Immuneering's EBITDA history runs 7 years deep, the most recent figure standing at -$15.3 million for Q1 2026.

• On a quarterly basis, EBITDA rose 0.97% year-over-year to -$15.3 million in Q1 2026; TTM through Mar 2026 was -$59.2 million, a 7.79% increase from a year earlier, with the FY2025 full-year figure at -$59.4 million, up 7.33% from the prior year.
• EBITDA retreated to -$15.3 million in Q1 2026 per IMRX's latest filing, from -$13.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$11.6 million in Q2 2022 and bottomed at -$18.6 million in Q4 2024.
• The 5-year median for EBITDA is -$14.8 million (2025), against an average of -$14.6 million.
• Across the five-year window, EBITDA sank 107.27% in 2022 and rose 25.89% in 2025, its largest moves.
• Year by year, EBITDA stood at -$14.0 million in 2022, then declined by 16.57% to -$16.3 million in 2023, then declined by 13.84% to -$18.6 million in 2024, then increased by 25.89% to -$13.8 million in 2025, then declined by 11.51% to -$15.3 million in 2026.
• Per Business Quant, the three latest IMRX EBITDA figures stand at -$15.3 million (Q1 2026), -$13.8 million (Q4 2025), and -$15.4 million (Q3 2025).